Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
BIOMEDevice Boston is an opportunity for over 4,000 engineers and executives and 400 suppliers in New England’s design and manufacturing industry to connect. It is an industry showcase created by UBM in partnership with Massachusetts Medical Device Industry Council (MassMEDIC).
The event – running May 3–4 at the Boston Convention and Exhibition Center – features several keynote speakers including Scott Whitaker, the president and CEO of AdvaMed, and Brahadeesh Chandrasekaran, senior industry analyst at Frost and Sullivan, as well as hundreds of supplier booths showcasing their latest technologies. Read more
Carmat shares are up today after the company said French regulators approved the resumption of a clinical trial for its artificial heart.
France’s national device & drug agency, the Agence Nationale de Sécurité du Médicament, said late yesterday that “Carmat has provided the elements allowing for the resumption of the trial, meeting satisfactory conditions of safety and risk control.” Read more
Shares in Intersect ENT fell slightly yesterday after the drug-device maker met expectations on Wall Street with its 1st quarter results.
The Menlo Park, Calif.-based company posted a loss of -$6.8 million, or -23¢ per share, on sales of $20.5 million for the 3 months ended March 31, for bottom-line growth of 20% on sales growth of 22.8% compared with the same period last year. Read more
Outset Medical said today it raised $76.5 million in a Series C equity funding round to support its Tablo hemodialysis system.
The Tablo system is an all-in-one dialysis machine which handles both water purification and dialysate production and is designed to be used in a variety of settings, CEO Leslie Trigg told MassDevice.com. Read more
LivaNova yesterday said it put up $72 million to acquire the remaining stake in Caisson Interventional, which is developing a implantable device to replace the heart’s mitral valve.
Maple Grove, Minn.-based Caisson’s transcatheter mitral valve replacement is designed to be delivered across the heaert’s septum via the femoral vein and can be repositioned or withdrawn before final deployment. The 1st patients in the 20-patient Prelude investigational device exemption study were implanted with the device last year. Read more